Kamada Ltd. is ramping up efforts to promote awareness of CYTOGAM, its CMV treatment for organ transplant recipients. With a substantial increase in CYTOGAM sales revenue, the company is launching a post-marketing research program to highlight the drug's benefits, explore new dosing strategies, and investigate additional applications to enhance CMV disease management and improve patients' quality of life.
